Recursion Pharmaceuticals, Inc. RXRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.47M-56.1% | $35.54M+682% | $5.18M-80.2% | $19.22M+33.3% | $14.75M+6.9% | ||
| $12.49M-42.8% | $14.28M+11.6% | $14.69M+21.6% | $20.16M+119% | $21.83M+95.5% | ||
| -$6.02M+15.0% | $21.26M— | -$9.51M-168% | -$938K-118% | -$7.08M-370% | ||
| -93%-44.9pp | 59.8%— | -183.8%-237pp | -4.9%-41.1pp | -48%-67.1pp | ||
| $87.9M-32.2% | $95.94M-2.4% | $121.06M+62.3% | $128.64M+74.0% | $129.63M+91.9% | ||
| $34.59M-36.7% | $33.66M-56.4% | $41.63M+10.3% | $46.65M+46.6% | $54.65M+74.0% | ||
| $134.98M-34.5% | $143.87M-23.6% | $177.38M+42.5% | $195.45M+70.0% | $206.11M+87.1% | ||
| -$128.51M+32.8% | -$108.33M+41.0% | -$172.2M-75.1% | -$176.23M-75.3% | -$191.37M-98.6% | ||
| -1,985.6%-688pp | -304.8%+3,738pp | -3,327.6%-2,950pp | -916.8%-219pp | -1,297.9%-599pp | ||
| $6.4M+157% | $232K-95.2% | $9.95M+271% | $4.33M+74.6% | -$11.28M-369% | ||
| -$122.11M+39.7% | -$108.1M+39.6% | -$162.25M-69.6% | -$171.9M-75.3% | -$202.65M-120% | ||
| -$4.6M-2,814% | —— | $3K-98.2% | $0+100% | -$158K+79.7% | ||
| -$117.5M+42.0% | -$108.12M+39.6% | -$162.25M-69.3% | -$171.9M-76.2% | -$202.49M-122% | ||
| -1,815.6%-442pp | -304.2%+3,631pp | -3,135.3%-2,768pp | -894.2%-218pp | -1,373.3%-711pp | ||
| -$0.22+56.0% | -$0.17+70.2% | -$0.36-5.9% | -$0.41-2.5% | -$0.50-28.2% | ||
| -$0.22+56.0% | -$0.17+70.2% | -$0.36-5.9% | -$0.41-2.5% | -$0.50-28.2% | ||
| 529.3M+31.4% | 447.4M+63.2% | 447M+58.2% | 417.4M+72.3% | 402.8M+70.7% | ||
| 529.3M+31.4% | 447.4M+63.2% | 447M+58.2% | 417.4M+72.3% | 402.8M+70.7% | ||
| $6.47M-56.1% | $35.54M+682% | $5.18M-80.2% | $19.22M+33.3% | $14.75M+6.9% | ||
| -$128.51M+32.8% | -$108.33M+41.0% | -$172.2M-75.1% | -$176.23M-75.3% | -$191.37M-98.6% | ||
| -$108.83M+36.7% | -$88.86M+48.0% | -$151.16M-65.8% | -$152.38M-66.4% | -$172.04M-93.4% | ||
| -$108.83M+36.7% | -$88.86M+48.0% | -$151.16M-65.8% | -$152.38M-66.4% | -$172.04M-93.4% | ||
| -1,681.6%-515pp | -250%+3,507pp | -2,920.9%-2,571pp | -792.7%-157pp | -1,166.7%-522pp | ||
| -$128.51M+32.8% | -$108.33M+41.0% | -$172.2M-75.1% | -$176.23M-75.3% | -$191.37M-98.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Recursion Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 7.2% and operating margin is -881.3%, with a -842.9% net margin.
- Where does Recursion Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.